How India Exports Prednisone to the World

In the United States, prednisone is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The extensive number of approved ANDAs underscores the competitive landscape of prednisone in the U.S. market. As of March 2026, there are no active import alerts or significant regulatory actions concerning prednisone, indicating a stable regulatory environment for its importation and distribution. The substantial export volume from India to the U.S., with 88.7% of total exports directed there, reflects the robust demand and established regulatory compliance of Indian manufacturers in the U.S. market.

In the European Union, prednisone is subject to national marketing authorizations, as it is not centrally authorized by the European Medicines Agency (EMA). The EMA's periodic safety update report (PSUR) single assessment for prednisone, concluded in November 2025, resulted in a variation to the product information, reflecting ongoing pharmacovigilance activities. Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards, ensuring product quality and safety. Compliance with these standards is essential for market access and maintaining the integrity of the supply chain.

Prednisone is included in the World Health Organization's Model List of Essential Medicines, highlighting its critical role in healthcare systems worldwide. The drug is recognized across various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications globally. This inclusion facilitates international trade and regulatory harmonization, benefiting exporters and healthcare providers alike.

In India, prednisone is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on prednisone, allowing market-driven pricing mechanisms. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Prednisone is a well-established generic medication with no active patents or exclusivity rights, leading to a highly competitive market with multiple manufacturers producing and exporting the drug. This competitive environment contributes to the affordability and widespread availability of prednisone globally.

In July 2022, the FDA granted orphan drug designation to prednisone for the treatment of Duchenne Muscular Dystrophy, recognizing its potential therapeutic benefits in rare diseases. This designation may encourage further research and development in this area.

In November 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on a variation to the marketing authorization for Akeega, recommending its use in combination with prednisone for specific prostate cancer indications. This development underscores the ongoing evaluation and expansion of prednisone's therapeutic applications in oncology.

These developments reflect the dynamic regulatory landscape and the continuous efforts to optimize prednisone's therapeutic use across various medical conditions.

India's pharmaceutical industry, including the production of Prednisone, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. In the fiscal year 2024-2025, India's API exports reached ₹41,500 crore, surpassing imports of ₹39,215 crore. However, imports from China constituted 74% of India's API import bill, underscoring a significant dependency on Chinese KSMs.

This reliance exposes the supply chain to vulnerabilities. For instance, in 2025, several Chinese API manufacturers faced shutdowns due to environmental non-compliance, leading to supply disruptions and increased costs for Indian pharmaceutical companies. Such events highlight the risks associated with over-dependence on a single country for critical raw materials.

Our proprietary data indicates that the top five Indian exporters account for 96.4% of Prednisone exports, with STRIDES PHARMA SCIENCE LIMITED alone contributing 42.2%. This high concentration poses a significant single-source risk. The Indian government's Production Linked Incentive (PLI) scheme, introduced in 2021 with an outlay of ₹6,940 crore, aims to bolster domestic API production and reduce reliance on imports. While this initiative has led to increased manufacturing capacity, the sector continues to face challenges from global supply chain vulnerabilities and competition.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the conflict in Iran led to the effective closure of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil passes. This disruption has halted oil tanker movements and affected the distribution of pharmaceuticals from India, leading to potential shortages and price increases. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding delays and increasing fuel costs. Air cargo has also been impacted due to closed airspace in several Middle Eastern countries, further straining the supply chain.

• Diversify API and KSM Sources: Reduce dependency on Chinese imports by establishing alternative supply chains with other countries and investing in domestic production capabilities.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to mitigate risks associated with high supplier concentration.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify potential disruptions early and respond proactively.

• Invest in Infrastructure: Support initiatives like the PLI scheme to build robust domestic manufacturing facilities, reducing reliance on imports and enhancing self-sufficiency.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including alternative shipping routes and inventory buffers, to navigate geopolitical and logistical challenges.

RISK_LEVEL: HIGH